CBD Granted Orphan Drug Status for Reperfusion Injury Prevention During Transplantation

This article originally appeared here.
Share this content:
The immunosuppressant and antiinflammatory effects of cannabidiol may attenuate the damage caused by ischemia and reperfusion during transplantation.
The immunosuppressant and antiinflammatory effects of cannabidiol may attenuate the damage caused by ischemia and reperfusion during transplantation.

The Food and Drug Administration (FDA) has granted Orphan Drug designation for cannabidiol (CBD) to prevent ischemia and reperfusion injury resulting from solid organ transplantation. 

The designation was granted to Revive Therapeutics, a company that specializes in cannabis-based pharmaceuticals. Previously, the Company was granted Orphan Drug status for cannabidiol in the treatment of autoimmune hepatitis. 

Ischemia/reperfusion injury can lead to higher rates of acute and chronic rejection of transplanted organs. The Company believes that the immunosuppressant and antiinflammatory effects of cannabidiol may attenuate the damage caused by ischemia and reperfusion during organ transplantation and could potentially be an alternative to more expensive strategies (ie, ischemic preconditioning, ischemic postconditiong, machine perfusion).

"This milestone builds on Revive's pharmaceutical strategy in developing novel cannabinoid therapies targeting both broad and rare inflammatory diseases and it supports our near-term product and business development strategy in commercializing novel cannabis-based therapies and potential partnering opportunities with licensed producers of cannabis and pharmaceutical companies.”" said Fabio Chianelli, President of Revive. 

For more information visit ReviveThera.com.

You must be a registered member of The Cardiology Advisor to post a comment.

Sign Up for Free e-Newsletters